Literature DB >> 7767184

Use of chloramphenicol as topical eye medication: time to cry halt?

M Doona, J B Walsh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7767184      PMCID： PMC2549610          DOI： 10.1136/bmj.310.6989.1217

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

1.  Adult pure red cell aplasia following topical ocular chloramphenicol.

Authors:  T Fernandez de Sevilla; J Alegre; T Vallespi; V Falco; J M Martinez-Vazquez
Journal:  Br J Ophthalmol       Date:  1990-10       Impact factor: 4.638

2.  Survey of patients taking topical medication at their first presentation to eye casualty.

Authors:  S A Buckley
Journal:  BMJ       Date:  1990-06-09

3.  Ophthalmic use of chloramphenicol.

Authors:  J D Stevens; G P Mission
Journal:  Lancet       Date:  1987-12-19       Impact factor: 79.321

4.  A fatal case of aplastic anemia following chloramphenicol (chloromycetin) therapy.

Authors:  M L RICH; R J RITTERHOFF; R J HOFFMANN
Journal:  Ann Intern Med       Date:  1950-12       Impact factor: 25.391

5.  Blood dyscrasias and topical ophthalmic chloramphenicol.

Authors:  F T Fraunfelder; R L Morgan; A A Yunis
Journal:  Am J Ophthalmol       Date:  1993-06-15       Impact factor: 5.258

6.  Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.

Authors:  F T Fraunfelder; G C Bagby; D J Kelly
Journal:  Am J Ophthalmol       Date:  1982-03       Impact factor: 5.258

7.  Letter: Chloramphenicol eye-drops and marrow aplasia.

Authors:  G Carpenter
Journal:  Lancet       Date:  1975-08-16       Impact factor: 79.321

Review 8.  Drug-induced aplastic anemia: pathogenesis and clinical aspects.

Authors:  D Malkin; G Koren; E F Saunders
Journal:  Am J Pediatr Hematol Oncol       Date:  1990

9.  Marrow aplasia following topical application of chloramphenicol eye ointment.

Authors:  S M Abrams; T J Degnan; V Vinciguerra
Journal:  Arch Intern Med       Date:  1980-04
  9 in total
  19 in total

Review 1.  Comparative review of topical ophthalmic antibacterial preparations.

Authors:  P Y Robert; J P Adenis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Neonatal methicillin resistant Staphylococcus aureus conjunctivitis.

Authors:  D N Sahu; S Thomson; A Salam; G Morton; P Hodgkins
Journal:  Br J Ophthalmol       Date:  2006-06       Impact factor: 4.638

3.  Is it time to stop using chloramphenicol on the eye? Fears are based on only six cases.

Authors:  R J Mulla; E Barnes; T R Rogers
Journal:  BMJ       Date:  1995-08-12

4.  Is it time to stop using chloramphenicol on the eye? Prospective study of aplastic anaemia should give definitive answer.

Authors:  E C Gordon-Smith; J C Marsh; C G Geary
Journal:  BMJ       Date:  1995-08-12

5.  Is it time to stop using chloramphenicol on the eye? Risk is low in short courses.

Authors:  A V Hall; S S Das; S Tabaqchali
Journal:  BMJ       Date:  1995-08-12

6.  Is it time to stop using chloramphenicol on the eye? General practitioners would expect to see aplasia roughly once each century.

Authors:  J Cox; E M Roderick
Journal:  BMJ       Date:  1995-08-12

7.  Is it time to stop using chloramphenicol on the eye? Safe in patients with no history of blood dyscrasia.

Authors:  R J Buckley; C M Kirkness; J J Kanski; A E Ridgway; A B Tullo; P G Watson
Journal:  BMJ       Date:  1995-08-12

8.  Possible association between ocular chloramphenicol and aplastic anaemia--the absolute risk is very low.

Authors:  J R Laporte; X Vidal; E Ballarín; L Ibáñez
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

9.  Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis).

Authors:  Preston Howard Blomquist
Journal:  Trans Am Ophthalmol Soc       Date:  2006

10.  Widespread ocular use of topical chloramphenicol: is there justifiable concern regarding idiosyncratic aplastic anaemia?

Authors:  C N McGhee; C N Anastas
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.